EPL
KROS icon

EDBI Pte Ltd’s Keros Therapeutics KROS Stock Holding History

EDBI Pte Ltd’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$160K Hold
10,105
– – 0.17% 14
2024
Q3 		$587K Hold
10,105
– – 0.79% 13
2024
Q2 		$462K Hold
10,105
– – 0.52% 15
2024
Q1 		$669K Hold
10,105
– – 0.75% 13
2023
Q4 		$402K Hold
10,105
– – 0.4% 17
2023
Q3 		$322K Hold
10,105
– – 0.35% 16
2023
Q2 		$406K Hold
10,105
– – 0.33% 16
2023
Q1 		$431K Hold
10,105
– – 0.48% 16
2022
Q4 		$485K Hold
10,105
– – 0.62% 15
2022
Q3 		$380K Hold
10,105
– – 0.4% 19
2022
Q2 		$279K Hold
10,105
– – 0.26% 18
2022
Q1 		$550K Hold
10,105
– – 0.37% 17
2021
Q4 		$591K Buy
+10,105
New +$504K 0.32% 13

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

EDBI Pte Ltd's KROS Position: Q4 2024 in Review

EDBI Pte Ltd held its Keros Therapeutics (KROS) position steady in Q4 2024 at 10,105 shares worth $160K. The position accounts for 0.17% of the portfolio, ranked #14.

EDBI Pte Ltd first reported a position in KROS in Q4 2021 and has held it in 13 quarters since. The position peaked at $669K in Q1 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • EDBI Pte Ltd held 10,105 shares of Keros Therapeutics worth $160K as of Q4 2024.
  • EDBI Pte Ltd left its Keros Therapeutics share count unchanged in Q4 2024.
  • Keros Therapeutics made up 0.17% of EDBI Pte Ltd's portfolio in Q4 2024, its #14 holding.
  • EDBI Pte Ltd first reported a position in Keros Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • EDBI Pte Ltd's Keros Therapeutics position peaked at $669K in Q1 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on EDBI Pte Ltd's 13F filing for Q4 2024, filed 4 Feb 2025.